|
Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826. |
|
|
Honoraria - AstraZeneca; Clovis Oncology; Eisai; Genmab; Merck; Tesaro |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro |
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Genmab; Merck; Roche/Genentech; Tesaro |
Research Funding - Abbvie (Inst); Genentech/Roche (Inst); Merck (Inst); Morphotek (Inst); Regeneron (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
Employment - Sarepta Therapeutics (I) |
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro |
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro |
|
|
|
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics |
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics |
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK |
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; MSD; Roche |
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD |
Research Funding - MSD; Roche; Sanofi |
|
|
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; MSD K.K; Takeda |
Consulting or Advisory Role - Kaken Pharmaceutical; MSD K.K |
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical |
|
|
Honoraria - AstraZeneca; BMS; Mediso; MSD Oncology; NeoPharm; Novartis; Roche |
Consulting or Advisory Role - MSD Oncology |
Research Funding - MSD (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - MSD Oncology (Inst) |
Consulting or Advisory Role - Amgen (Inst); Gen (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Roche; Takeda (Inst) |
Speakers' Bureau - MSD Oncology (Inst); Novartis (Inst); Polipharma (Inst); Roche (Inst) |
Research Funding - Amgen (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
Mivael Olivera Hurtado de Mendoza |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - GlaxoSmithKline; Merck |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BMS; Eisai; IMV (Inst); Ipsen; Janssen; Merck; Pfizer |
Research Funding - AstraZeneca Canada (Inst); Bayer (Inst); IMV (Inst); Merck (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck Sharp & Dohme |
|
|
Employment - Merck Sharp & Dohme |
|
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck Sharp & Dohme |
|
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck Sharp & Dohme |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; Merck Serono; MSD; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma |
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar |
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; GlaxoSmithKline; PharmaMar; Roche |
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup |